SIBIA Neurosciences, Inc. v. Cadus Pharmaceutical Corporation

Adam L.K. Philipp

Case Conclusion Date:February 23, 1999

Practice Area:Patent Infringement

Outcome:Defendant lost, reversed on appeal

Description:SIBIA sued Cadus for infringing its patent by using the patented screening methods. The district court awarded SIBIA an $18 million reasonable royalty for Cadus' infringing action, and denied Cadus' motions for judgment as a matter of law and for a new trial. Cadus then appealed to the Court of Appeals for the Federal Circuit. The Federal Circuit ultimately held SIBIA's patent invalid for obviousness, citing a single reference that disclosed the cells used in SIBIA's claimed methods, and concluding that general knowledge in the art provided the motivation to modify the reference and use the prior art cells in the methods claimed in SIBIA's patent.